Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00845728
Other study ID # CQAB149B2348
Secondary ID 2008-007944-33
Status Completed
Phase Phase 3
First received February 15, 2009
Last updated September 16, 2013
Start date March 2009
Est. completion date July 2012

Study information

Verified date September 2013
Source Novartis
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationAustria: Federal Office for Safety in Health CareSlovakia: State Institute for Drug ControlCanada: Health CanadaIsrael: Ministry of HealthSpain: Spanish Agency of MedicinesEstonia: The State Agency of MedicineLithuania: State Medicine Control Agency - Ministry of HealthFinland: Finnish Medicines AgencyBelgium: Federal Agency for Medicinal Products and Health ProductsUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)India: Drugs Controller General of IndiaHungary: National Institute of PharmacyIceland: Icelandic Medicines Control AgencyColombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y AlimentosAustralia: Department of Health and Ageing Therapeutic Goods AdministrationDenmark: Danish Medicines AgencyCzech Republic: State Institute for Drug ControlTurkey: Ministry of HealthLatvia: State Agency of MedicinesPhilippines: Bureau of Food and DrugsRussia: FSI Scientific Center of Expertise of Medical ApplicationGermany: Federal Institute for Drugs and Medical DevicesNetherlands: The Central Committee on Research Involving Human Subjects (CCMO)Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsArgentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia MedicaPortugal: National Authority of Medicines and Health Products (INFARMED, I.P.)Taiwan: Department of HealthSweden: Medical Products AgencySwitzerland: SwissmedicRomania: National Medicines AgencyPeru: Instituto Nacional de SaludCosta Rica: Ministry of Health Costa RicaItaly: The Italian Medicines AgencySouth Africa: Medicines Control CouncilChina: Food and Drug AdministrationVenezuela: Ministry of Health and Social DevelopmentBrazil: National Health Surveillance AgencyThailand: Food and Drug AdministrationMexico: National Institute of Public Health, Health SecretariatNew Zealand: Ministry of Health
Study type Interventional

Clinical Trial Summary

This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks


Recruitment information / eligibility

Status Completed
Enrollment 3439
Est. completion date July 2012
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Both
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Male and female adults aged =40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure

- Patients diagnosed with COPD at age 40 and over and with a current diagnosis of severe COPD and including:

1. Smoking history of at least 10 pack years, both current and ex-smokers are eligible

2. A documented history of at least 1 moderate or severe exacerbation in the previous 12 months

Exclusion Criteria:

- Patients who have received systemic corticosteroids and/or antibiotics for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period

- Patients who have had a respiratory tract infection within 6 weeks prior to screening

- Patients with concomitant pulmonary disease

- Patients with a history of asthma

- Patients with diabetes Type I or uncontrolled diabetes Type II

- Any patient with lung cancer or a history of lung cancer

- Patients with a history of certain cardiovascular comorbid conditions

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Indacaterol 150 µg
Indacaterol 150 µg o.d. delivered via SDDPI
Tiotropium
Tiotropium 18 µg o.d. delivered via handihaler®

Locations

Country Name City State
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Capital Federal Buenos Aires
Argentina Novartis Investigative Site Mar del Plata Buenos Aires
Argentina Novartis Investigative Site Mendoza
Argentina Novartis Investigative Site Pilar Buenos Aires
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Australia Novartis Investigative Site Adelaide South Australia
Australia Novartis Investigative Site Bankstown New South Wales
Australia Novartis Investigative Site Daw Park South Australia
Australia Novartis Investigative Site Heidelberg Victoria
Australia Novartis Investigative Site Nedlands Western Australia
Australia Novartis Investigative Site Parkville Victoria
Australia Novartis Investigative Site Tauranga, New Zealand
Austria Novartis Investigative Site Feldbach
Austria Novartis Investigative Site Gänserndorf
Austria Novartis Investigative Site Grieskirchen
Austria Novartis Investigative Site Hallein
Austria Novartis Investigative Site Linz
Austria Novartis Investigative Site Perg
Austria Novartis Investigative Site Zwettl
Belgium Novartis Investigative Site Aalst
Belgium Novartis Investigative Site Antwerpen
Belgium Novartis Investigative Site Bruxelles
Belgium Novartis Investigative Site Bruxelles
Belgium Novartis Investigative Site Duffel
Belgium Novartis Investigative Site Eupen
Belgium Novartis Investigative Site Framerie
Belgium Novartis Investigative Site Geraardsbergen
Belgium Novartis Investigative Site Gilly
Belgium Novartis Investigative Site Godinne
Belgium Novartis Investigative Site Gozée
Belgium Novartis Investigative Site Herentals
Belgium Novartis Investigative Site Jambes
Belgium Novartis Investigative Site Jette
Belgium Novartis Investigative Site Kortrijk
Belgium Novartis Investigative Site Leuven
Belgium Novartis Investigative Site Liege
Belgium Novartis Investigative Site Liège
Belgium Novartis Investigative Site Malmedy
Belgium Novartis Investigative Site Menen
Belgium Novartis Investigative Site Montigny-le-tilleul
Belgium Novartis Investigative Site Namur
Belgium Novartis Investigative Site Oostende
Belgium Novartis Investigative Site Turnhout
Brazil Novartis Investigative Site Caxias do Sul RS
Brazil Novartis Investigative Site Goiania GO
Brazil Novartis Investigative Site Juiz de Fora MG
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Porto Alegre RS
Brazil Novartis Investigative Site Rio de Janeiro RJ
Brazil Novartis Investigative Site São Paulo SP
Canada Novartis Investigative Site Burlington Ontario
Canada Novartis Investigative Site Calgary Alberta
Canada Novartis Investigative Site Calgary Alberta
Canada Novartis Investigative Site Edmonton Alberta
Canada Novartis Investigative Site Kelowna British Columbia
Canada Novartis Investigative Site Mississauga Ontario
Canada Novartis Investigative Site Moncton New Brunswick
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Newmarket Ontario
Canada Novartis Investigative Site Ottawa Ontario
Canada Novartis Investigative Site Sainte-Foy Quebec
Canada Novartis Investigative Site Sherbrooke Quebec
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Vancouver British Columbia
Canada Novartis Investigative Site Winnipeg Manitoba
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Changsha Hunan
China Novartis Investigative Site Changsha City Hunan
China Novartis Investigative Site Chongqing
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shen Yang
China Novartis Investigative Site Shengyang Liaoning
China Novartis Investigative Site Shijiazhuang Hebei
China Novartis Investigative Site Xi'an Shanxi
China Novartis Investigative Site Xi'an Shanxi
Colombia Novartis Investigative Site Barranquilla
Colombia Novartis Investigative Site Bogotá
Colombia Novartis Investigative Site Medellín
Costa Rica Novartis Investigative Site San Francisco de Asís
Costa Rica Novartis Investigative Site San Jose
Czech Republic Novartis Investigative Site Beroun
Czech Republic Novartis Investigative Site Ceske Budejovice
Czech Republic Novartis Investigative Site Cesky Krumlov
Czech Republic Novartis Investigative Site Cvikov
Czech Republic Novartis Investigative Site Karlovy Vary
Czech Republic Novartis Investigative Site Karlovy Vary
Czech Republic Novartis Investigative Site Kurim
Czech Republic Novartis Investigative Site Kyjov CZE
Czech Republic Novartis Investigative Site Novy Jicin
Czech Republic Novartis Investigative Site Ostrava
Czech Republic Novartis Investigative Site Ostrava - Hrabuvka
Czech Republic Novartis Investigative Site Praha 6
Czech Republic Novartis Investigative Site Prerov
Czech Republic Novartis Investigative Site Rokycany
Czech Republic Novartis Investigative Site Rudna
Czech Republic Novartis Investigative Site Strakonice
Czech Republic Novartis Investigative Site Teplice
Czech Republic Novartis Investigative Site Zatec
Denmark Novartis Investigative Site Aalborg
Denmark Novartis Investigative Site Århus
Denmark Novartis Investigative Site Copenhagen NV
Denmark Novartis Investigative Site Hellerup
Denmark Novartis Investigative Site Helsingor
Denmark Novartis Investigative Site Hvidovre
Denmark Novartis Investigative Site Odense C
Estonia Novartis Investigative Site Rakvere
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tartu
Finland Novartis Investigative Site Helsinki
Finland Novartis Investigative Site HUS
Finland Novartis Investigative Site Jyvaskyla
Finland Novartis Investigative Site Pori
Finland Novartis Investigative Site Porvoo
Finland Novartis Investigative Site Tampere
Finland Novartis Investigative Site Turku
France Novartis Investigative Site Beuvry
France Novartis Investigative Site Bourges
France Novartis Investigative Site Ferolles-Attily
France Novartis Investigative Site Lyon cedex 04
France Novartis Investigative Site Montpellier
France Novartis Investigative Site Nantes
France Novartis Investigative Site Nice Cedex 1
France Novartis Investigative Site Ollioules Cedex
France Novartis Investigative Site Paris
France Novartis Investigative Site Perpignan Cedex
France Novartis Investigative Site Pessac
France Novartis Investigative Site Reims
France Novartis Investigative Site St Michel
France Novartis Investigative Site Vandoeuvre les Nancy
Germany Novartis Investigative Site Bad Woerishofen
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Bonn
Germany Novartis Investigative Site Bonn
Germany Novartis Investigative Site Borstel
Germany Novartis Investigative Site Dachau
Germany Novartis Investigative Site Euskirchen
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Fürstenwalde/Spree
Germany Novartis Investigative Site Güstrow
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hoyerswerda
Germany Novartis Investigative Site Landsberg
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Mainz
Germany Novartis Investigative Site Marburg
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site München
Germany Novartis Investigative Site Neu-Ulm
Germany Novartis Investigative Site Neumünster
Germany Novartis Investigative Site Neuss
Germany Novartis Investigative Site Oranienburg
Germany Novartis Investigative Site Radebeul
Germany Novartis Investigative Site Ratingen
Germany Novartis Investigative Site Rüdersdorf
Germany Novartis Investigative Site Teterow
Germany Novartis Investigative Site Ulm
Germany Novartis Investigative Site Wedel
Germany Novartis Investigative Site Witten
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Cegled
Hungary Novartis Investigative Site Debrecen
Hungary Novartis Investigative Site Deszk
Hungary Novartis Investigative Site Mosonmagyarovar
Hungary Novartis Investigative Site Nyiregyhaza
Hungary Novartis Investigative Site Sopron
Hungary Novartis Investigative Site Szarvas
Hungary Novartis Investigative Site Tatabanya
Hungary Novartis Investigative Site Torokbalint
Iceland Novartis Investigative Site Reykjavik
India Novartis Investigative Site Ahmedabad Gujrat-India
India Novartis Investigative Site Ahmedabad Gujrat
India Novartis Investigative Site Bangalore Karnataka
India Novartis Investigative Site Bangalore Karnataka
India Novartis Investigative Site Calicut Kerala
India Novartis Investigative Site Coimbatore Tamil Nadu
India Novartis Investigative Site Hyderabad Andhra Pradesh
India Novartis Investigative Site Hyderabad Andhra Pradesh
India Novartis Investigative Site Indore Madhya Pradesh
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Mangalore Karnataka
India Novartis Investigative Site Nagpur - Maharashtra
India Novartis Investigative Site Nagpur - Maharastra
India Novartis Investigative Site New Delhi Delhi
India Novartis Investigative Site Noida New Delhi
India Novartis Investigative Site Panjim
India Novartis Investigative Site Trivandrum Kerala
India Novartis Investigative Site Vellore Tamil Nadu
Israel Novartis Investigative Site Ashkelon
Israel Novartis Investigative Site Jerusalem
Israel Novartis Investigative Site Ramat Gan
Israel Novartis Investigative Site Rehovot
Israel Novartis Investigative Site Tel-Aviv
Italy Novartis Investigative Site Acquaviva delle Fonti BA
Italy Novartis Investigative Site Bari BA
Italy Novartis Investigative Site Bergamo BG
Italy Novartis Investigative Site Brescia BS
Italy Novartis Investigative Site Cassino FR
Italy Novartis Investigative Site Catanzaro CZ
Italy Novartis Investigative Site Cava Dei Tirreni SA
Italy Novartis Investigative Site Cona FE
Italy Novartis Investigative Site Cuasso al Monte VA
Italy Novartis Investigative Site Genova GE
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Modena MO
Italy Novartis Investigative Site Napoli
Italy Novartis Investigative Site Orbassano TO
Italy Novartis Investigative Site Palermo PA
Italy Novartis Investigative Site Parma PR
Italy Novartis Investigative Site Pisa
Italy Novartis Investigative Site Pordenone PN
Italy Novartis Investigative Site Prato PO
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Siena SI
Italy Novartis Investigative Site Teramo TE
Italy Novartis Investigative Site Trieste TS
Italy Novartis Investigative Site Verona VR
Latvia Novartis Investigative Site Riga LV
Latvia Novartis Investigative Site Riga
Lithuania Novartis Investigative Site Kaunas
Lithuania Novartis Investigative Site Klaipeda
Lithuania Novartis Investigative Site Siauliai
Lithuania Novartis Investigative Site Utena
Lithuania Novartis Investigative Site Vilnius
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Monterrey Nuevo León
Mexico Novartis Investigative Site Pachuca Hidalgo
Mexico Novartis Investigative Site San Luis Potosí
Netherlands Novartis Investigative Site Almelo
Netherlands Novartis Investigative Site Breda
Netherlands Novartis Investigative Site Eindhoven
Netherlands Novartis Investigative Site Enschede
Netherlands Novartis Investigative Site Rotterdam
Netherlands Novartis Investigative Site Sneek
Netherlands Novartis Investigative Site Zwolle
Peru Novartis Investigative Site Cercado de Lima Lima
Peru Novartis Investigative Site Jesus Maria Lima
Peru Novartis Investigative Site La Victoria Lima
Peru Novartis Investigative Site Miraflores Lima
Peru Novartis Investigative Site San Borja Lima
Peru Novartis Investigative Site San Isidro Lima
Peru Novartis Investigative Site San Martin de Porres Lima
Peru Novartis Investigative Site San Miguel Lima
Peru Novartis Investigative Site Santiago de Surco Lima
Philippines Novartis Investigative Site Quezon City Metro Manila
Philippines Novartis Investigative Site Quezon City Metro Manila
Philippines Novartis Investigative Site Quezon City
Philippines Novartis Investigative Site Quezon City
Poland Novartis Investigative Site Gdansk
Poland Novartis Investigative Site Gdansk
Poland Novartis Investigative Site Katowice
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Warszawa
Poland Novartis Investigative Site Warszawa
Poland Novartis Investigative Site Wroclaw
Portugal Novartis Investigative Site Amadora
Portugal Novartis Investigative Site Coimbra
Portugal Novartis Investigative Site Coimbra
Portugal Novartis Investigative Site Lisboa
Portugal Novartis Investigative Site Lisboa
Portugal Novartis Investigative Site Lisboa
Portugal Novartis Investigative Site Porto
Romania Novartis Investigative Site Brasov Jud. Brasov
Romania Novartis Investigative Site Bucharest District 3
Romania Novartis Investigative Site Bucharest
Romania Novartis Investigative Site Cluj-Napoca
Romania Novartis Investigative Site Constanta Jud. Constanta
Romania Novartis Investigative Site Iasi Jud. Iasi
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Ekaterinburg
Russian Federation Novartis Investigative Site Ekaterinburg
Russian Federation Novartis Investigative Site Kazan
Russian Federation Novartis Investigative Site Kazan Tatarstan Republic
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Samara
Russian Federation Novartis Investigative Site Sankt-Peterburg
Russian Federation Novartis Investigative Site St. Petersburg
Russian Federation Novartis Investigative Site St.-Petersburg
Slovakia Novartis Investigative Site Bratislava Slovak Republic
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Kosice Slovak Republic
Slovakia Novartis Investigative Site Lucenec
Slovakia Novartis Investigative Site Nove Zamky
Slovakia Novartis Investigative Site Poprad
Slovakia Novartis Investigative Site Spisska Nova Ves Slovak Republic
South Africa Novartis Investigative Site Bloemfontein
South Africa Novartis Investigative Site Bloemfontein
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Durban
Spain Novartis Investigative Site Alicante Comunidad Valenciana
Spain Novartis Investigative Site Alzira Comunidad Valenciana
Spain Novartis Investigative Site Barcelona Cataluña
Spain Novartis Investigative Site Barcelona Cataluña
Spain Novartis Investigative Site Barcelona Cataluña
Spain Novartis Investigative Site Caceres Extremadura
Spain Novartis Investigative Site Gijon Asturias
Spain Novartis Investigative Site Illescas Castilla la Mancha
Spain Novartis Investigative Site Jerez de La Frontera Andalucia
Spain Novartis Investigative Site La Coruna Galicia
Spain Novartis Investigative Site Lugo Galicia
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Malaga Andalucia
Spain Novartis Investigative Site Mérida Extremadura
Spain Novartis Investigative Site Plasencia Extremadura
Spain Novartis Investigative Site Pozuelo de Alarcón Madrid
Spain Novartis Investigative Site Requena Comunidad Valenciana
Spain Novartis Investigative Site Salt Cataluña
Spain Novartis Investigative Site Sanlúcar de Barrameda Andalucia
Spain Novartis Investigative Site Sant Boi de Llobregat Cataluña
Spain Novartis Investigative Site Santiago de Compostela Galicia
Spain Novartis Investigative Site Sevilla Andalucia
Spain Novartis Investigative Site Terrassa Cataluña
Spain Novartis Investigative Site Valladolid Castilla y Leon
Spain Novartis Investigative Site Vic Cataluña
Sweden Novartis Investigative Site Göteborg
Sweden Novartis Investigative Site Göteborg
Sweden Novartis Investigative Site Luleå
Sweden Novartis Investigative Site Lund
Sweden Novartis Investigative Site Malmö
Sweden Novartis Investigative Site Skellefteå
Sweden Novartis Investigative Site Stockholm
Sweden Novartis Investigative Site Sundsvall
Switzerland Novartis Investigative Site Bern
Switzerland Novartis Investigative Site Crans-Montana
Switzerland Novartis Investigative Site Faltigberg-Wald ZH
Switzerland Novartis Investigative Site Lausanne
Switzerland Novartis Investigative Site St. Gallen
Switzerland Novartis Investigative Site Thun
Switzerland Novartis Investigative Site Winterthur
Switzerland Novartis Investigative Site Zuerich
Taiwan Novartis Investigative Site Taichung
Taiwan Novartis Investigative Site Taichung
Taiwan Novartis Investigative Site Taipei
Taiwan Novartis Investigative Site Taipei
Taiwan Novartis Investigative Site Taipei County
Thailand Novartis Investigative Site Bangkok
Thailand Novartis Investigative Site Chiang Mai
Thailand Novartis Investigative Site Khon Kaen
Thailand Novartis Investigative Site Songkla
Turkey Novartis Investigative Site Ankara
Turkey Novartis Investigative Site Canakkale
Turkey Novartis Investigative Site Diskapi / Ankara
Turkey Novartis Investigative Site Emek / Ankara
Turkey Novartis Investigative Site Gaziantep
Turkey Novartis Investigative Site Isparta
Turkey Novartis Investigative Site Istanbul
Turkey Novartis Investigative Site Izmir
Turkey Novartis Investigative Site Kahramanmaras
Turkey Novartis Investigative Site Kecioren / Ankara
Turkey Novartis Investigative Site Kozlu / Zonguldak
Turkey Novartis Investigative Site Malatya
Turkey Novartis Investigative Site Mersin
Turkey Novartis Investigative Site Yenisehir/Izmir
United Kingdom Novartis Investigative Site Ash Vale Surrey
United Kingdom Novartis Investigative Site Belfast
United Kingdom Novartis Investigative Site Bexhill-on-Sea
United Kingdom Novartis Investigative Site Bradford
United Kingdom Novartis Investigative Site Bristol
United Kingdom Novartis Investigative Site Cambridge
United Kingdom Novartis Investigative Site Crawley West Sussex
United Kingdom Novartis Investigative Site Lancashire
United Kingdom Novartis Investigative Site Lancashire
United Kingdom Novartis Investigative Site Liverpool
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Newcastle Upon Tyne Newcastle
United Kingdom Novartis Investigative Site Newport
United Kingdom Novartis Investigative Site Stockport
United Kingdom Novartis Investigative Site Stockport
United Kingdom Novartis Investigative Site Surrey
United Kingdom Novartis Investigative Site Swansea England
United Kingdom Novartis Investigative Site Warminster
United Kingdom Novartis Investigative Site Watford
United Kingdom Novartis Investigative Site Windsor
Venezuela Novartis Investigative Site Barquisimeto Estado Lara
Venezuela Novartis Investigative Site Maracaibo Estado Zulia
Venezuela Novartis Investigative Site Valencia Estado Carabobo

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Argentina,  Australia,  Austria,  Belgium,  Brazil,  Canada,  China,  Colombia,  Costa Rica,  Czech Republic,  Denmark,  Estonia,  Finland,  France,  Germany,  Hungary,  Iceland,  India,  Israel,  Italy,  Latvia,  Lithuania,  Mexico,  Netherlands,  Peru,  Philippines,  Poland,  Portugal,  Romania,  Russian Federation,  Slovakia,  South Africa,  Spain,  Sweden,  Switzerland,  Taiwan,  Thailand,  Turkey,  United Kingdom,  Venezuela, 

Outcome

Type Measure Description Time frame Safety issue
Primary Trough Forced Expiratory Volume in 1 Second (FEV1). The primary objective of the study was to demonstrate the non-inferiority of indacaterol vs. tiotropium with respect to 24 hour post dose (trough) FEV1 after 12 weeks of treatment in patients with severe COPD. Trough FEV1 was defined as the average of the 23 hours 10 min and the 23 hours 45 min post dose values. Trough FEV1 was analyzed using a mixed model for the PPS-S. The model contained treatment as a fixed effect with the baseline FEV1, FEV1 prior to inhalation and FEV1 15 min post-inhalation of salbutamol/albuterol (components of SABA reversibility at Visit 2), FEV1 prior to inhalation and FEV1 60 min post-inhalation of ipratropium (components of anti-cholinergic reversibility at Visit 3) as covariates. Smoking history (current or ex-smoker) was included as a factor in the model. 12 weeks No
Secondary Rate of COPD Exacerbations COPD exacerbations were defined as :Worsening of 2 or more major symptoms for at least 2 consecutive days: dyspnea; sputum volume; suputum purulence AND requiring treatment with systemic corticosteroids and/or antibiotics OR Worsening of any 1 major symptom together with any 1 of the following minor symptoms for at least 2 consecutive days: Sore throat; colds; fever without other cause; increased cough; increase wheeze AND requiring treatment with systemic glucocorticosteroids and/or antibiotics. The rate was analyzed using a linear model assuming a negative binomial distribution for the PPS-E. The time at risk for a patient was defined as the length of time the patient was in the study and the log(length of time in the study) was used as the offset variable in the model. 52 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy